Publications

T cell receptors (TCRs) can enable detection and elimination of cancer cells via recognition of cancer-specific peptides presented on human leukocyte antigen (HLA). We speculated that shared cancer antigens could be recognized by recurrent ("public") TCRs, which might be identifiable using statistical methods.

Background Zinc finger and BTB domain-containing protein 32 (ZBTB32) is a CXXCG motif-containing transcription factor with context-dependent roles in immune regulation. ZBTB32 represses CIITA during plasma cell differentiation, restrains CD8-positive T cell effector and memory responses, and supports natural killer cell proliferation following viral infection.

Background Despite demonstrated benefits of immune checkpoint inhibitors (ICIs) across four pivotal phase III trials, patients with mismatch repair proficient/microsatellite stable (pMMR/MSS) endometrial cancer exhibit attenuated and heterogenous benefit. Although ICI-containing regimens are now standard of care regardless of MMR status, no validated biomarker exists to identify which pMMR/MSS patients derive benefit.

Background Predictive biomarkers for immune checkpoint inhibitor (ICI) benefit remain imperfect in routine clinical practice. The Tempus Immune Profile Score (IPS) is a multi-modal biomarker using DNA/RNA sequencing to produce a continuous 0–100 score, stratifying patients as IPS-High (IPS-H) or IPS-Low (IPS-L) for expected ICI benefit.

Background Expression of L-type amino acid transporter 1 (LAT1; gene symbol: SLC7A5) is enriched across several cancers and has been associated with poor prognosis and cancer progression. However, the relationship between LAT1 expression, the tumor microenvironment, and outcomes remains understudied in colorectal cancers.

Background PRAME is an immunogenic cancer-testis antigen and an emerging target for adoptive cellular therapies and other immune-based treatments. While PRAME expression has been described in several sarcoma histologies, its prevalence, immune correlates, and prognostic significance across sarcomas have not been comprehensively evaluated.

Background Spatial transcriptomics (ST) offers critical value for mapping the tumor microenvironment (TME) and discovering immuno-oncology biomarkers, but high cost and operational complexity limit adoption in routine practice. Virtual ST offers a scalable alternative by utilizing deep learning to predict spatially resolved gene expression directly from standard, cost-effective Hematoxylin and Eosin (H&E) slides.

Background Immune checkpoint inhibition (ICI) has transformed the treatment of microsatellite instability-high (MSI-H) colorectal cancer (CRC), although a significant subset of patients exhibit primary resistance. We reported two transcriptomic subtypes of MSI-H colon adenocarcinoma (COAD) with divergent outcomes following ICI: C1 Inflamed (responsive) and C2 Goblet-like (resistant).

Background The immunologic effects of trastuzumab deruxtecan (T-DXd) are incompletely defined, partly due to the lack of immunocompetent models that support trastuzumab binding. This limitation has constrained mechanistic understanding and development of rational combination strategies. Methods We developed HER2, a minimally modified murine HER2 receptor that permits trastuzumab binding without inducing xenoantigen-driven immune responses in vivo.

Background The PD-L1 combined positive score (CPS) is a widely used but imperfect biomarker in head and neck squamous cell carcinoma (HNSCC). The Immune Profile Score (IPS), Tempus’ AI-developed multi-modal biomarker integrating genomics and transcriptomics, offers a potentially more nuanced alternative.